Friday, May 31, 2013: 1:00 PM-3:00 PM
Lake Mizzel AB
1:00 PM
Alemtuzumab is Efficacious in Highly-Active RRMS Patients in CARE-MS II
Stephen Krieger, MD, Mount Sinai Medical Center, New York, NY, USA;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, Quebec, Canada;
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA;
Alasdair J Coles, MD, University of Cambridge, Cambridge, UK;
Christian Confavreux, MD, University Claude Bernard, Lyon, France;
Edward J Fox, MD, MS Clinic of Central Texas, Round Rock, TX, USA;
Hans-Peter Hartung, MD, Heinrich-Heine University, Dusseldorf, Germany;
Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz, Lodz, Poland;
Howard L Weiner, MD, Brigham and Women's Hospital Center for Neurologic Diseases;
Tamara A Miller, MD, Advanced Neurology of Colorado, Ft Collins, CO, USA;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Stephen L Lake, ScD, Genzyme, Cambridge, MA, USA;
David H Margolin, MD, Genzyme, Cambridge, MA, USA;
Michael A Panzara, MD, Genzyme, Cambridge, MA, USA;
Alastair Compston, MD, University of Cambridge, Cambridge, UK
1:20 PM
No Effect on Incidence of Infection After Therapy Switch to Fingolimod
Christopher LaGanke, MD, North Central Neurology Associates, PC;
Daniel Wynn, MD, FACN, FAASM, Consultants in Neurology MS Center;
Kevin McCague, MA, Novartis Pharmaceuticals Corporation;
Luigi M Barbato, MD, Novartis Pharmaceuticals Corporation;
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation
1:40 PM
Patient Preference for Risk Benefit Trade-Off of Disease Modifying Therapy Attributes
Leslie S Wilson, PhD, University of California San Francisco;
Aimee Loucks, PharmD, Kaiser Permanente;
Gregory Gipson, PharmD, University of California San Francisco;
Christine Bui, MS, University of California San Francisco;
Emmanuelle Waubant, MD, PhD, University of California, San Francisco;
Douglas S. Goodin, MD, University of California, San Francisco;
Bruce Cree, MD/PhD MCR, University of California, San Francisco;
Mary Owen, NP, University of California, San Francisco;
Amy Schwartzburg, NP, University of California, San Francisco;
Charles E McCulloch, PhD, University of California, San Francisco
2:20 PM
Peginterferon Beta-1a in Relapsing Multiple Sclerosis: Phase 3 ADVANCE
Peter A Calabresi, MD, FAAN, Johns Hopkins University, Baltimore, MD, USA;
Bernd C Kieseier, MD, Department of Neurology, Heinrich-Heine University, Dusseldorf, Germany;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research;
Laura Balcer, MD, MSCE, NYU Langone Medical Center;
Alexey Boyko, MD, Moscow MS Center at RSMU, Moscow, Russia;
Jean Pelletier, MD, PhD, Departments of Neurology and Research (CRMBM), CHU Timone, Marseille, France;
Serena Hung, MD, Biogen Idec Inc;
Ali Seddighzadeh, MD, Biogen Idec Inc;
Shifang Liu, PhD, Biogen Idec Inc;
Ying Zhu, PhD, Biogen Idec Inc;
Bjorn Sperling, MD, Biogen Idec Inc;
Aaron Deykin, MD, Biogen Idec Inc
2:40 PM
Development of Multipotent Adult Progenitor Cells for Treatment of Multiple Sclerosis
Jason A Hamilton, PhD, Athersys Inc.;
Rochelle Cutrone, MS, Athersys Inc.;
Jordan Hecker, BS, Case Western Reserve University;
Janet Krasno, BS, Case Western Reserve University;
Krysta Wyatt, MS, Case Western Reserve University;
Sarah A Busch, PhD, Athersys Inc.;
Lianhua Bai, PhD, Case Western Reserve University;
Robert J Deans, PhD, Athersys Inc.;
Robert H Miller, PhD, Case Western Reserve University;
Robert W Mays, PhD, Athersys Inc.
![[ Visit Client Website ]](images/banner.gif)